Science news

Pieper Veterinary Partners with Portland Veterinary Emergency and Specialty Care Hospital in Portland Maine

MIDDLETOWN, Conn., Oct. 16, 2023 /PRNewswire/ -- Pieper Veterinary, a Connecticut-based family of primary, specialty, and emergency care veterinary hospitals, is excited to announce they have...

While Medication May Offer Relief, Christ Offers True and Lasting Peace

Xulon Press presents the answer to debilitating fear and anxiety. KNIFE RIVER, Minn., Oct. 16, 2023 /PRNewswire-PRWeb/ -- Author Theresa Ellison writes of the power...

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Data include three late-breaking abstracts, underscoring Astellas' efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO, Oct. 15, 2023 /PRNewswire/ -- Astellas...

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have...

World Health Summit kicks off in Berlin

Experts from around the world meet at the most important forum on global health BERLIN, Oct. 15, 2023 /PRNewswire/ -- The World Health Summit 2023,...

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Novel cancer immunotherapy is being assessed in nationwide SURVIVE trial in adults with glioblastoma, and in studies for other applications in children and adults....

Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PT-112's mechanism of action promotes immunogenic cancer cell death through ribosomal biogenesis inhibition and organelle stress NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics...

Latest articles